Moving forward in the treatment of cholangiocarcinoma

doi:10.4251/wjgo.v13.i12.1939

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 12

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4211)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

313

WORD

HTML

2341

Figures (1-1)

194

Tables (1-2)

223

Sum=3158

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

366

Download

687

Sum=1053

Dec 15, 2021 (publication date) through Jul 23, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Dec 15, 2021; 13(12): 1939-1955
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.1939

Moving forward in the treatment of cholangiocarcinoma

Tommaso M Manzia, Alessandro Parente, Ilaria Lenci, Bruno Sensi, Martina Milana, Carlo Gazia, Alessandro Signorello, Roberta Angelico, Giuseppe Grassi, Giuseppe Tisone, Leonardo Baiocchi

Tommaso M Manzia, Bruno Sensi, Carlo Gazia, Roberta Angelico, Giuseppe Tisone, Hepato-Pancreato-Biliary and Transplant, Department of Surgery, University of Rome Tor Vergata, Rome 00133, Italy

Alessandro Parente, The Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham B15 2TH, United Kingdom

Ilaria Lenci, Martina Milana, Alessandro Signorello, Giuseppe Grassi, Leonardo Baiocchi, Hepatology Unit, University of Tor Vergata, Rome 00133, Italy

Author contributions: Manzia TM contributed to acquisition of data, analysis and interpretation, drafting of manuscript and critical revision; Parente A, Lenci I, Sensi B, Milana M, Gazia C, Signorello A, Angelico R, Grassi G and Tisone G contributed to acquisition of data and critical revision; Baiocchi L contribute to proposal of study, study conception, correction of manuscript and critical revision.

Conflict-of-interest statement: The authors declare no conflict of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Leonardo Baiocchi, MD, PhD, Associate Professor, Hepatology Unit, University of Tor Vergata, Viale Oxford 31, Rome 00133, Italy. baiocchi@uniroma2.it

Received: March 16, 2021
Peer-review started: March 16, 2021
First decision: May 3, 2021
Revised: May 14, 2021
Accepted: October 14, 2021
Article in press: October 14, 2021
Published online: December 15, 2021
Processing time: 273 Days and 9.9 Hours

Core Tip

Core Tip: Cholangiocarcinoma is a lethal malignancy characterized by a poor survival. In this review we discuss in detail the actual treatment and the future therapeutic perspectives for this cancer. Systemic and surgical strategies are reported with the corresponding results. Improved knowledge of this malignancy and a multidisciplinary therapeutic approach are likely to improve the cholangiocarcinoma outcome in the future.